发明申请
US20050014743A1 Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
审中-公开
NMDA受体拮抗剂和选择性5-羟色胺再摄取抑制剂的组合用于治疗抑郁症和其他情绪障碍
- 专利标题： Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
- 专利标题（中）： NMDA受体拮抗剂和选择性5-羟色胺再摄取抑制剂的组合用于治疗抑郁症和其他情绪障碍
-
申请号： US10857597申请日： 2004-05-27
-
公开(公告)号： US20050014743A1公开(公告)日： 2005-01-20
- 发明人: Sandeep Gupta , Gary Samoriski
- 申请人： Sandeep Gupta , Gary Samoriski
- 申请人地址： US NY New York
- 专利权人： Forest Laboratories, Inc.
- 当前专利权人： Forest Laboratories, Inc.
- 当前专利权人地址： US NY New York
- 主分类号： A61K
- IPC分类号： A61K20060101 ; A61K31/13 ; A61K31/16 ; A61K31/343 ; A61K31/551 ; A61K45/06
摘要：
The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.
信息查询
